hydroxychloroquine for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	deaths E	clinical improvement E	death or ventilation E
COVID 19 hospitalized meta-analysis
Abd-Elsalam NCT04353336		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	97/97	inconclusive
Chen NCT04384380		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	21/12	inconclusive
NO COVID-19 (Lyngbakken) NCT04316377		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	27/26	inconclusive
RECOVERY NCT04381936		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	1561/3155	safety concern
SOLIDARITY (WHO study) HCQ NCT04315948		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	947/906	inconclusive
COVID-19 mild to moderate meta-analysis
FACCT Trial NCT04392973		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	125/129	inconclusive
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine NCT04322123		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	221/227	safety concern
16 studies excluded by filtering options (14 RCT / 2 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis